We present a 19-year-old man with alveolar paratesticular rhabdomyosarcoma (RMS) who underwent restaging with both 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/ computed tomography (CT) and 99mTc-fibroblast activation protein inhibitor (FAPI)-46 single-photon… Click to show full abstract
We present a 19-year-old man with alveolar paratesticular rhabdomyosarcoma (RMS) who underwent restaging with both 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)/ computed tomography (CT) and 99mTc-fibroblast activation protein inhibitor (FAPI)-46 single-photon emission computed tomography (SPECT)/CT after the initial surgery. Despite normal retroperitoneal lymph nodes on CT, 18F-FDG PET/CT revealed a recurrent mass in the spermatic cord stump and an inguinal lymph node, which was not detected by 99mTc-FAPI SPECT/CT. Our case highlights the superior efficacy of 18F-FDG PET/CT compared with 99mTc-FAPI SPECT/CT in restaging paratesticular RMS, consistent with previous studies demonstrating the utility of 18F-FDG PET/CT in the initial staging of RMS. This report underscores the importance of selecting the optimal imaging modality for accurate disease assessment and management in this aggressive and rare tumor subtype.
               
Click one of the above tabs to view related content.